Italia markets closed

Dow Jones
39.870,40
+312,29(+0,79%)
Nasdaq
16.741,58
+230,40(+1,40%)
Nikkei 225
38.385,73
+29,67(+0,08%)
EUR/USD
1,0883
+0,0061(+0,57%)
Bitcoin EUR
60.649,88
+4.047,53(+7,15%)
CMC Crypto 200
1.386,13
+118,19(+9,32%)

NVCR Sep 2024 20.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

3,0000

0,0000

(0,00%)

In data: 02:29PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in